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Molecular Medicine SelectImmune responses are subject to many layers of regulation such that their effect is precisely calibrated. New approaches
to selectively alter the intensity and type of immune response for therapeutic benefit are the topic of this issue’sMolecular
Medicine Select. This includes the recent discovery of amodifier gene that shapes the activity of lung neutrophils to affect
the severity of cystic fibrosis. Other exciting discoveries link variants in a gene involved in antiviral immunity to the etiology
of type 1 diabetes and examine the role of Toll-like receptors in shaping effector and regulatory T cell responses.
Researchers also report that autophagy enhances vaccine efficacy and have identified a compound that prevents
mucosal transmission of simian immunodeficiency virus in rhesus macaques.
Neutrophils Take Sides in Cystic Fibrosis
Cystic fibrosis is characterized by the buildup of mucus in the lungs, cycles of infec-
tion and inflammation, and progressive destruction of the airway. Although the
genetic basis of cystic fibrosis is known—it is an autosomal recessive disorder
caused by mutations in the ion channel CFTR—less clear are the reasons why the
severity of the disease varies markedly from person to person. Gu et al. (2009) sought
to identify modifier genes for cystic fibrosis by conducting a genome-wide associa-
tion study in patients grouped according to the severity of disease pathology. They
discover that single-nucleotide polymorphisms (SNPs) in the human gene encoding
the transcriptional coregulator IFRD1 correlate with differential severity of the disease.
The authors establish that IFRD1 expression is particularly high in neutrophils, a cell
type that mediates acute inflammatory responses to infection, and further show
that neutrophils from mice lacking IFRD1 display a diminished capacity to rapidly
release reactive oxygen species, which neutrophils use to kill invading bacteria. Hence, in mice, loss of IFRD1 impairs bacte-
rial killing but restrains the type of inflammatory response that has been shown to contribute to tissue damage in cystic fibrosis
patients. To connect the SNPs in IFRD1 and altered neutrophil function in humans, Gu et al. examine the function of neutro-
phils from healthy human subjects grouped according to their IFRD1 genotype. They show that the same IFRD1 SNPs that
correlate with disease severity in cystic fibrosis are linked to normal variations in neutrophil activity in healthy subjects.
This provides compelling evidence that neutrophils are the cell type in which the genetic variability in IFRD1 forges its impact
on cystic fibrosis pathology. Additionally, this groundbreaking work implies that IFRD1 polymorphisms are likely to affect
immune responses in healthy individuals in other types of infection, a discovery that by itself warrants further investigation.
Y.Y. Gu et al. (2009). Nature. Published online February 25, 2009. 10.1038/nature07811.
Antiviral Gene Variants Decrease Diabetes Risk
Genome-wide association studies can identify loci that affect risk for a particular disease. However, given that these loci can
include many genes and may encompass many disease-linked single-nucleotide polymorphisms (SNPs), it is a daunting and
uncertain task to prove that a particular gene or polymorphism is causal for the disease. In an effort to understand the genetics
of type 1 diabetes, Nejentsev et al. (2009) recently resequenced the exons and splice junctions of ten candidate genes iden-
tified previously. The authors used 454 sequencing to analyze these genes in 480 patients with type 1 diabetes and an equal
number of controls. This approach led to the identification of four rare SNPs in interferon-induced helicase C domain-contain-
ing protein 1 (IFIH1, also known asMDA5), a gene that encodes a cytoplasmic protein that detects RNA from invading picor-
naviruses. These SNPs, which are associated with reduced risk of type 1 diabetes, are expected to alter the structure or
expression of IFIH1. Two of the SNPs alter predicted splice sites. One SNP introduces a substitution of a highly conserved
amino acid, and another introduces a nonsense mutation that would establish a premature stop codon such that the protein
product would lack the C-terminal helicase domain. Given that IFIH1 triggers production of interferon-b to marshal the
immune response upon recognition of viral RNA, future efforts might seek to link this pathway to the generation or activation
of the autoreactive T cells that lead to type 1 diabetes. Moreover, these efforts validate resequencing as a powerful means to
find rare causative variants and to establish a persuasive link between genes identified in genome-wide association studies
and mechanisms of disease.
S. Nejentsev et al. (2009). Science. Published online March 5, 2009. 10.1126/science.1167728.
Vitamin A Metabolism Takes a Toll on TH17 Cells
Receptors of the innate immune system recognize molecules associated with microbes. In their recent work, Manicassamy
et al. (2009) reveal how the innate and adaptive immune responses to zymosan, a component of yeast cell walls, differ
depending upon which of its two known zymosan receptors is engaged—Toll-like receptor 2 (TLR2) or dectin-1. They
show that TLR2 signaling in dendritic cells leads to an increase in the expression of retinaldehyde dehydrogenase type 2
(Raldh2), an enzyme that converts vitamin A to retinoic acid. Retinoic acid then acts in an autocrine manner to suppress
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production of proinflammatory cytokines. The net effect of this is to induce T regulatory (Treg)
cells and simultaneously diminish the responses of T helper type 1 (TH1) and TH17 cells. In
contrast, when zymosan signals through dectin-1, proinflammatory cytokines are produced,
which elevates TH1 and TH17 responses to exacerbate autoimmunity. That the samemicrobial
compound can elicit such starkly opposing effects depending on which receptor it engages
gives an indication of how tightly the immune system maintains the balance between aggres-
sively challenging invaders while avoiding tissue damage that might result from an overexu-
berant reaction. The authors propose that microbes, such as Mycobacterium tuberculosis,
that cause chronic infectionsmight exploit these different signaling pathways to tip the balance
in favor of Treg responses as a strategy of immune evasion. If so, selectively suppressing TLR2
signaling or selectively engaging dectin-1 could bolster the immune response against some
chronic infections.
S. Manicassamy et al. (2009). Nat. Med. Published online March 1, 2009. 10.138/nm.1925.
Autophagy Gives Vaccination a Shot in the Arm
The efficacy of some vaccines is highly variable. Such is the case of the bacillus
Calmette-Gue´rin (BCG) attenuated strain of Mycobacterium bovis that when used
as a live vaccine in humans confers protection against M. tuberculosis infection in
many, but not all, individuals. Jagannath et al. (2009) now show that stimulating au-
tophagy, the tightly regulated cellular process that degrades long-lived proteins and
organelles, improves the efficacy of vaccination by enhancing antigen presentation
by dendritic cells. In vitro, treatment of antigen-presenting cells with the mTOR
inhibitor rapamycin, which stimulates autophagy, increases the localization of my-
cobacteria to autophagosomes and lysosomes. In so doing, rapamycin enhances
the presentation of antigen Ag58B, an epitope that stimulates the main T helper 1
(TH1) response that confers immunity to tuberculosis. When autophagy is sup-
pressed, this enhancement in the presentation of Ag58B is blocked. Moreover,
the authors show in amousemodel of tuberculosis vaccination that rapamycin treat-
ment of dendritic cells boosts the TH1 response and confers protection against virulent tuberculosis. Interestingly, prior work
has shown that Toll-like receptor (TLR) signaling also stimulates autophagy in antigen-presenting cells, suggesting thatmodu-
lation of autophagy may be a feature of the immune response that is commonly regulated. Hence, the authors speculate that
live vaccines engineered to activate specific TLR pathwaysmight afford greater protection against tuberculosis than is offered
by current approaches.
C. Jagannath et al. (2009). Nat. Med. 15, 267–276.
Mucosal Border Guard
Stoppingmicrobes right at their point of contact with the hostmay be the best defense against many types of infection. Li et al.
(2009) now report that rhesus macaques are protected from simian immunodeficiency virus (SIV) by a compound called glyc-
erol monolaurate. This antimicrobial impairs the recruitment of CD4+ T cells, SIV’s preferred target cell, to mucosal sites of
virus entry. The authors report that contact between SIV and the vaginal and cervical mucosa of macaques leads to the rapid
influx of CD4+ T cells that are drawn to the site of initial infection by the local production of inflammatory chemokines, including
macrophage inflammatory protein-3a (MIP-3a). They then provide evidence that it may be possible to disrupt this mucosal
signaling pathway by using glycerol monolaurate, which in prior work has been shown to suppress production of MIP-3a.
This treatment quells the recruitment of CD4+ T cells, and without CD4+ T cells at the infection site, SIV lacks a safe haven
for its expansion and dissemination. Given the similarity between SIV infection in macaques and HIV-1 infection in humans,
these findings may lead to new approaches to block the mucosal transmission of HIV-1. Future work will undoubtedly involve
large-scale efforts in macaques to more thoroughly gauge the effectiveness of this approach in blocking infection and will
further delve into the mechanism of action for glycerol monolaurate.
Q. Li et al. (2009). Nature. Published online March 4, 2009. 10.1038/nature07831.
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